摘要程序性死亡蛋白1(PD?1)及其配体(PD?L1)已经被证明在逃避机体的免疫系统中发挥重要的作用.近年来,PD?1／PD?L1阻断在很多恶性肿瘤中显示出较为明显的临床效果,这些恶性肿瘤包括恶性黑色素瘤、肾细胞癌、经典霍奇金淋巴瘤、非小细胞肺癌等. PD?1／PD?L1信息通路可能成为恶性肿瘤患者免疫治疗的新靶点.但目前免疫治疗在恶性骨肿瘤中的研究较少,PD?1／PD?L1在其中的临床研究进展仍有待阐明.文章分析了肿瘤免疫PD?1／PD?L1信号通路及作用机制,探讨了目前常用PD?1／PD?L1单抗在恶性骨肿瘤中的应用前景,以期为中国开展基于PD?1／PD?L1信号通路的恶性骨肿瘤治疗提供理论依据.

abstractsProgrammed death receptor 1 (PD?1) and its ligand PD?L1 have been shown to play an important role in evading the immune system. In recent years, PD?1／PD?L1 blockade has shown significant clinical effects in many malignancies, including malignant melanoma, renal cell carcinoma, classic Hodgkin lymphoma, non?small cell lung cancer and so on. PD?1／PD?L1 signaling pathway has become a new target of immunotherapy in patients with malignant tumors. However, there are few researches on immunotherapy in malignant bone tumors, and the progress of clinical research on PD?1／PD?L1 remains to be elucidated. This review started from the mechanism of PD?1／PD?L1 signaling in tumor immunity, and analyzed the application prospect of PD?1／PD?L1 antibodies in malignant bone tumors. We hope to provide a theoretical basis for the treatment of malignant bone tumors based on PD?1／PD?L1 signaling pathway in China.